Compare Quest Diagnostics Inc (DGX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.7. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| DGX | QDTY | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $238.50 | $46.71 |
52-Week Low | $173.49 | $36.57 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
QDTY trades at $39.75, showing minimal daily movement with a -0.13% decline. The technical picture remains neutral overall with bearish moving averages, while the company demonstrates consistent dividend distributions through its weekly payout structure. Recent YieldMax ETF announcements highlight ongoing distribution activities through mid-2026.
The stock presents income-focused appeal through regular distributions, though fundamental metrics remain unavailable for comprehensive valuation assessment. Key considerations include reliance on ETF distribution strategies and market volatility exposure. The neutral technical stance suggests limited near-term directional momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
